Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness
Lu Li1, Shilei Yang1, Fengqi Fang2
1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Frontiers in Pharmacology
|November 27, 2024
Abstract:
[This corrects the article DOI: 10.3389/fphar.2024.1382120.].
Keywords:
HER-2-positive metastatic breast cancerT-DM1T-DXdcost-effectiveness analysisnetwork meta-analysispyrotinib plus capecitabineMore Related Videos
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
82
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
